Compare Procter & Gamble Health with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs UNICHEM LAB - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH UNICHEM LAB PROCTER & GAMBLE HEALTH/
UNICHEM LAB
 
P/E (TTM) x 52.7 57.0 92.5% View Chart
P/BV x 4.8 0.6 778.9% View Chart
Dividend Yield % 9.9 2.3 439.7%  

Financials

 PROCTER & GAMBLE HEALTH   UNICHEM LAB
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
UNICHEM LAB
Mar-19
PROCTER & GAMBLE HEALTH/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs3,549292 1,215.4%   
Low Rs1,301182 715.0%   
Sales per share (Unadj.) Rs511.4167.7 305.0%  
Earnings per share (Unadj.) Rs61.3-3.6 -1,688.1%  
Cash flow per share (Unadj.) Rs74.05.9 1,245.7%  
Dividends per share (Unadj.) Rs440.004.00 11,000.0%  
Dividend yield (eoy) %18.11.7 1,075.0%  
Book value per share (Unadj.) Rs927.8372.3 249.2%  
Shares outstanding (eoy) m16.6070.38 23.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.71.4 335.5%   
Avg P/E ratio x39.6-65.3 -60.6%  
P/CF ratio (eoy) x32.839.9 82.1%  
Price / Book Value ratio x2.60.6 410.6%  
Dividend payout %717.9-110.2 -651.6%   
Avg Mkt Cap Rs m40,25716,680 241.4%   
No. of employees `0001.12.6 43.6%   
Total wages/salary Rs m1,3132,393 54.9%   
Avg. sales/employee Rs Th7,486.74,535.2 165.1%   
Avg. wages/employee Rs Th1,157.6919.8 125.9%   
Avg. net profit/employee Rs Th897.2-98.2 -913.6%   
INCOME DATA
Net Sales Rs m8,49011,801 71.9%  
Other income Rs m244984 24.8%   
Total revenues Rs m8,73412,785 68.3%   
Gross profit Rs m1,482-835 -177.5%  
Depreciation Rs m211674 31.3%   
Interest Rs m075 0.0%   
Profit before tax Rs m1,514-600 -252.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m563-343 -163.8%   
Profit after tax Rs m1,017-256 -398.2%  
Gross profit margin %17.5-7.1 -246.7%  
Effective tax rate %37.157.3 64.9%   
Net profit margin %12.0-2.2 -553.4%  
BALANCE SHEET DATA
Current assets Rs m15,34320,384 75.3%   
Current liabilities Rs m1,9605,029 39.0%   
Net working cap to sales %157.6130.1 121.1%  
Current ratio x7.84.1 193.1%  
Inventory Days Days49105 46.5%  
Debtors Days Days28135 21.1%  
Net fixed assets Rs m1,2099,023 13.4%   
Share capital Rs m166141 117.9%   
"Free" reserves Rs m15,23526,058 58.5%   
Net worth Rs m15,40126,199 58.8%   
Long term debt Rs m00-   
Total assets Rs m17,59531,496 55.9%  
Interest coverage xNM-7.0-  
Debt to equity ratio x00-  
Sales to assets ratio x0.50.4 128.8%   
Return on assets %5.8-0.6 -1,010.0%  
Return on equity %6.6-1.0 -677.3%  
Return on capital %10.3-2.0 -513.1%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,6368,188 20.0%   
Fx outflow Rs m4,368596 732.9%   
Net fx Rs m-2,7327,592 -36.0%   
CASH FLOW
From Operations Rs m-1,304-3,278 39.8%  
From Investments Rs m12,697-2,860 -443.9%  
From Financial Activity Rs m-301-24 1,241.7%  
Net Cashflow Rs m11,093-4,690 -236.5%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 15.1 120.5%  
FIIs % 1.0 3.0 33.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 31.7 91.8%  
Shareholders   28,591 20,176 141.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   FRESENIUS KABI ONCO.  ABBOTT INDIA  PANACEA BIOTECH  CIPLA  GSK PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 87 Points Higher; Telecom and Auto Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the telecom sector and auto sector.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Oct 14, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 8-QTR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS